tbuckley/cabot-search huggingface dataset:
Sorafenib and everolimus (RAD001) in the treatment of patients with advanced clear cell renal carcinoma (RCC): A Sarah Cannon Research Institute phase I/II trial.
Authors: D. M. Waterhouse, W. C. Penley, C. D. Webb, F. A. Greco, H. A. Burris, J. D. Hainsworth
Journal: Journal of Clinical Oncology (2011)

4629 Background: Sorafenib and everolimus are standard agents with different targets (VEGFR and m-TOR, respectively) for the treatment of advanced RCC. Combined use of these agents may improve efficacy. This phase I/II trial established the maximum tolerated dose (MTD) for these agents when used in combination, and then evaluated this combination in advanced RCC. Methods: Eligible patients had metastatic or unresectable recurrent clear cell RCC, and had received 0 or 1 previous regimen for advanced RCC. Additional entry criteria: ECOG PS 0–1, prior nephrectomy (unless medically inappropriate), no active CNS metastasis, adequate liver/kidney/marrow function, informed consent. Sorafenib was given PO daily; everolimus PO once weekly. Patients were evaluated for response every 8 weeks; treatment continued until progression. Results: 10 patients entered the phase I portion; the MTDs were sorafenib 400mg PO qd and everolimus 35mg PO weekly (DLTs: rash, hand-foot syndrome). 50 patients enrolled in the phase II portion (total 56 treated at MTD dosing). Efficacy results after median 9.6 months follow-up (Table). Median treatment duration was 5 months (range 0.3–25.4+). Grade 3/4 toxicity: fatigue (21%), pain (18%), proteinuria (9%), hypophosphatemia (7%). Six patients (11%) stopped treatment due to toxicity. Conclusions: Concurrent use of sorafenib and everolimus required use of 50% of the single agent doses. The regimen was active and tolerable; however, benefit versus sequential single agents is not suggested. All (N=56) First line (N=40) Previous treatment (N=16) ORR 3 (5%) 3 (8%) 0 Clinical benefit (CR+PR+SD) 42 (75%) 32 (80%) 10 (63%) Median PFS, mo. 5.91 (95% CI: 5.03, 9.17) 6.97 (95% CI: 5.45, 9.17) 4.6 (95% CI: 1.84, 23.43) Progression-free at 6 months 28 (50%)* 21 (53%)* 7 (44%)* * 2 pts have not reached 6 months on-study (1 pt per arm).
SB1518: A Potent and Orally Active JAK2 Inhibitor for the Treatment of Myeloproliferative Disorders.
Authors: Kee C. Goh, Wai C. Ong, Changyong Hu, Hannes Hentze, Ai L. Liang, Walter Stunkel, Yong C. Tan, Kanda Sangthongpitag, Siok K. Goh, Shirly Sieh, Zahid Q. Bonday, Anthony D. William, Angeline Lee, Stephanie Blanchard, Te C. Liu, Martin Sattler, James D. Griffin, Brian W. Dymock, Ethirajulu Kantharaj, Jeanette M. Wood
Journal: Blood (2007)
Case 9-1983
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, Betty U. McNeely, L.Jack Faling, Eugene J. Mark
Journal: New England Journal of Medicine (1983)

Presentation of CaseA 60-year-old man was admitted to the hospital because of increasing dyspnea.He was well until five years earlier, when angina pectoris developed. Thirty-nine months before admission the angina became more severe, and propranolol was prescribed. Because of profound fatigue isosorbide dinitrate was substituted, with satisfactory control of pain. He was then well and able to walk several miles daily until six weeks before entry, when he began to have exertional dyspnea outdoors in the cold and dyspnea on climbing stairs. Three weeks before admission a physician found crackling rales at both lung bases, without peripheral edema. . . .
90Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin’s Lymphoma: First Results of the International Randomized Phase 3 First-Line Indolent Trial (FIT) in 414 Patients.
Authors: Anton Hagenbeek, Angelika Bischof-Delaloye, John A. Radford, Ama Rohatiner, Gilles Salles, Achiel Van Hoof, Barbara Putz, Michael Kunz, Franck Morschhauser
Journal: Blood (2007)
Molecular Ellipticity of Circulating Albumin-Bilirubin Complex is a Reliable Prognostic Measure of Severity of Acute on Chronic Liver Failure (ACLF)
Authors: S. Das, J.S. Maras, S. Hussain, C. Sudarshan, S.M. Shastry, S.K. Sharma, P. Balaram, S.K. Sarin
Journal: Journal of Hepatology (2016)
A Randomised Dose De-Escalation Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years: Final Analysis of Response and Toxicity
Authors: Stephen P. Mulligan, Devinder Gill, Paul Turner, William E. P. Renwick, Maya Latimer, Naomi Mackinlay, Leanne Berkahn, David Simpson, Philip Campbell, Cecily J Forsyth, Gavin Cull, Rosemary Harrup, Melanie Sulda, Giles Best, Mathias Bressel, Juliana Di Iulio, Bryone J Kuss
Journal: Blood (2014)
Interferon Regulatory Factor 1 Restricts Hepatitis E Virus Replication by Activating STAT1 to Induce Antiviral Interferon-Stimulated Genes
Authors: L. Xu, X. Zhou, W. Wang, Y. Wang, Y. Yin, L.J.W. Van Der Laan, D. Sprengers, H.J. Metselaar, M.P. Peppelenbosch, Q. Pan
Journal: Journal of Hepatology (2016)
Angiotensin Neprilysin Inhibition for Patients With Heart Failure
Authors: Milton Packer
Journal: JAMA Cardiology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Next Generation Sequencing for HCV Genotyping and Optional Identification of Resistance-Associated Variants
Authors: E. Rakhmanaliev, Z. Rui, W. Huang, K.S. Poon, W.C. Cui, J.K. Mui, E. Koay, E. Passomsub, W. Chantratita, G. Michel
Journal: Journal of Hepatology (2016)
An exploratory study investigating the metabolic activity and local cytokine profile in patients with melanoma treated with pazopanib and paclitaxel
Authors: S. Thurneysen, P.F. Cheng, H.W. Nagel, M. Kunz, N. Jaberg-Bentele, M. Nägeli, M. Ziegler, E. Guenova, S.M. Goldinger, J. Mangana, M.P. Levesque, R. Dummer
Journal: British Journal of Dermatology (2016)

There is a medical need for new drugs in patients with BRAF wild‐type metastatic melanoma. Pazopanib is a multitarget tyrosine kinase inhibitor with antitumour and antiangiogenic activity. The primary aim was to investigate the metabolic response to pazopanib monotherapy and pazopanib plus paclitaxel in patients with BRAF wild‐type melanoma. Secondary end points were the early cytokine and chemokine profiles and histological findings. Pazopanib (400 mg twice daily) was administered orally from days 1 to 10 and from days 14 to 70. An intravenous infusion with paclitaxel (150 mg m−2 body surface) was administered on days 14, 35 and 56. Metabolic response evaluation was performed before treatment, after treatment with pazopanib (day 10) and after treatment with pazopanib and paclitaxel (day 70). Skin biopsy of metastatic tissue for chemokine and cytokine expression analysis and histology and immunohistochemistry (CD68, CD163) evaluation, and blood samples were taken at the same time points. Two patients failed screening and 17 were dosed. Of 67 adverse events, nine (13%) were grade 3 or 4. Five of 14 evaluable patients had a partial metabolic response at day 10 under pazopanib monotherapy. The response rate at day 70 under combined pazopanib–paclitaxel treatment was 0%. Immunohistochemistry revealed an increase of M2‐like macrophages in nonresponders compared with responders. We observed a significant upregulation of five cytokines (CXCL1, CXCL2, CXCL13, CCL22 and SPP1) in responding vs. nonresponding lesions. Overall, the median progression‐free survival was 70 days (range 5–331), which did not differ significantly between responders (148 days) and nonresponders (70 days, P = 0·17). In this patient population pazopanib efficacy was limited. Response is associated with low M2‐like macrophage density and increased expression of several chemokines.
Letter by Kochilas et al Regarding Article, “Report of the National Heart, Lung, and Blood Institute Working Group: An Integrated Network for Congenital Heart Disease Research”
Authors: Lazaros K. Kochilas, Matthew E. Oster, Logan G. Spector
Journal: Circulation (2016)

We read with interest the article by Pasquali et al 1 exploring opportunities and challenges toward an integrated data network for congenital heart disease research.We fully agree with the authors' conclusion that there is a need for additional integration and collaboration to understand and improve the outcomes for patients with congenital heart disease.A particular gap that needs to be addressed is the lack of long-term and longitudinal outcomes for this population.To achieve this goal, it is important to leverage existing datasets to the maximum extent, and as the authors note, linking existing datasets together may not be sufficient to address this issue.In that regard, we want to bring to the attention of the authors and the readers of Circulation the approach we have undertaken with the data from the PCCC (Pediatric Cardiac Care Consortium) registry.The PCCC registry contains data on >150 000 patients who have undergone >250 000 procedures (cardiac operations, cardiac catheterizations, and electrophysiology procedures) at 47 US centers between 1982 and 2011, with direct identifiers available for patients enrolled up to April 2003 (time of imposing the stricter Health Insurance Portability and Accountability Act [HIPAA] regulations).That makes the PCCC the longest existing registry for interventions for congenital heart disease and, to our knowledge, the only one containing direct identifiers that can be used for assessing long-term outcomes for patients enrolled up to April 2003. 2 The availability of direct identifiers in this PCCC cohort makes it very useful to monitor some long-term outcomes of patients enrolled in this registry by linking with national registries. 3The PCCC data already have been linked successfully with the National Death Index (NDI) and the United Network for Shared Organs (UNOS), and this linkage is expected to provide significant information regarding the long-term outcomes for the altered history of congenital heart disease after palliative or corrective procedures.Linkages such as that of the PCCC with NDI and UNOS will address many of the weaknesses identified by the authors in Table 1 of their article, most notably the identified weakness of limited longer term and longitudinal outcomes data.Future work to address this weakness may include additional linkages or, when feasible, contacting participants in the registry to learn about poorly surveilled outcomes.
Inhibition of the Histone Demethylase LSD1 Combined with Caloric Restriction or IGF1/Insulin Inhibition Leads to Durable Responses in a Preclinical Model of Acute Myeloid Leukemia
Authors: Luca Mazzarella, Tiphanie Durfort, Rani Pallavi, Elena Mylonas, Paolo Falvo, Anna Giulia Sanarico, Massimo Stendardo, Luciano Giaco', Anna Russo, Lucilla Luzi, Massimiliano Mazza, Giulia De Conti, Paola Vianello, Pier Luigi Rossi, Elena Ceccacci, Mohamed Elgendy, Marco Giorgio, Ciro Mercurio, Saverio Minucci, Pier Giuseppe Pelicci
Journal: Blood (2015)
Comparison of Frequencies of Drug-Drug Interactions between Sofosbuvir/Ledipasvir and Ombitasvir/Dasabuvir/Paritaprevir/Ritonavir +/− Ribavirin among HIV/HCV Coinfected Patients
Authors: C. Schriever, A. Ahmed, K.R. Delehanty, J. Yager, G. Farrow, R. Kashtan, T. Lodise, N. Patel
Journal: Journal of Hepatology (2016)
Iron refractory iron deficiency anemia: a heterogeneous disease that is not always iron refractory
Authors: Albertine E. Donker, Charlotte C.M. Schaap, Vera M. J. Novotny, Roel Smeets, Tessa M. A. Peters, Bert L. P. van den Heuvel, Martine F. Raphael, Anita W. Rijneveld, Inge M. Appel, Andre J. Vlot, A. Birgitta Versluijs, Michel van Gelder, Bernd Granzen, Mirian C.H. Janssen, Alexander J.M. Rennings, Frank L. van de Veerdonk, Paul P.T. Brons, Dirk L. Bakkeren, Marten R. Nijziel, L. Thom Vlasveld, Dorine W. Swinkels
Journal: American Journal of Hematology (2016)

TMPRSS6 variants that affect protein function result in impaired matriptase‐2 function and consequently uninhibited hepcidin production, leading to iron refractory iron deficiency anemia (IRIDA). This disease is characterized by microcytic, hypochromic anemia and serum hepcidin values that are inappropriately high for body iron levels. Much is still unknown about its pathophysiology, genotype–phenotype correlation, and optimal clinical management. We describe 14 different TMPRSS6 variants, of which 9 are novel, in 21 phenotypically affected IRIDA patients from 20 families living in the Netherlands; 16 out of 21 patients were female. In 7 out of 21 cases DNA sequencing and multiplex ligation dependent probe amplification demonstrated only heterozygous TMPRSS6 variants. The age at presentation, disease severity, and response to iron supplementation were highly variable, even for patients and relatives with similar TMPRSS6 genotypes. Mono‐allelic IRIDA patients had a milder phenotype with respect to hemoglobin and MCV and presented significantly later in life with anemia than bi‐allelic patients. Transferrin saturation (TSAT)/hepcidin ratios were lower in IRIDA probands than in healthy relatives. Most patients required parenteral iron. Genotype alone was not predictive for the response to oral iron. We conclude that IRIDA is a genotypically and phenotypically heterogeneous disease. The high proportion of female patients and the discrepancy between phenotypes of probands and relatives with the same genotype, suggest a complex interplay between genetic and acquired factors in the pathogenesis of IRIDA. In the absence of inflammation, the TSAT/hepcidin ratio is a promising diagnostic tool, even after iron supplementation has been given. Am. J. Hematol. 91:E482–E490, 2016. © 2016 Wiley Periodicals, Inc.
Dasabuvir and Ombitasvir/Paritaprevir/Ritonavir with or without Ribavirin in Patients with HIV-HCV Coinfection: Real Life Interim Analysis of an Italian Multicentre Compassionate Use Program
Authors: E. Teti, A. Ricciardi, A. Antinori, M. Galli, G. Rizzardini, A. Di Biagio, G. Angarano, R. Bruno, C. Mussini, A. De Luca, A. Cattelan, A. Lazzarin, G. Taliani, A. D’Arminio Monforte, C.M. Mastroianni, G. Di Perri, F. Maggiolo, M. Puoti, F. Castelli, A. Gori, N. Boffa, B. Cacopardo, A. Giacometti, G. Parruti, V. Vullo, A. Chirianni, A. Pennica, C. Pasquazzi, L. Sighinolgi, E. Gentilotti, L. Sarmati, M. Andreoni
Journal: Journal of Hepatology (2016)
Growth Differentiation Factor 15 (GDF-15) A Surrogate Marker of Endothelial Dysfunction Correlates with Severity and Predicts Short-Term Survival of Patients with Alcoholic Hepatitis
Authors: J. Altamirano, D. Rodrigo-Torres, M. Coll, S. Affó, O. Morales-Ibanez, J. Michelena, D. Blaya, M. Llopis, C. Millán, I. Graupera, L. Perea, B. Aguilar, R. Bataller, P. Gines, P. Sancho-Bru, J. Caballeria
Journal: Journal of Hepatology (2016)
Tudca Protects against Endoplasmic Reticulum Stress-Induced Inflammasome Activation and Hepatocyte Death in Non-Alcoholic Steatohepatitis
Authors: C. Lebeaupin, E. Proics, C.-H.D. de Bieville, D. Rousseau, S. Bonnafous, S. Patouraux, A. Tran, P. Gual, B. Bailly-Maitre
Journal: Journal of Hepatology (2016)
Treatment Selection and Practice Patterns for the Management of High-Risk Chronic Lymphocytic Leukemia (CLL) in the US: An Analysis of the Impact of Risk Stratification on Treatment Selection from the Connect CLL® Registry
Authors: Anthony Mato, Chadi Nabhan, Christopher Flowers, Neil E. Kay, Thomas J. Kipps, David L. Grinblatt, Nicole Lamanna, Mark Kozloff, Kristen Sullivan, E. Dawn Flick, Pavel Kiselev, Shriya Bhushan, Arlene S. Swern, Jeff P. Sharman
Journal: Blood (2015)
Is high pre-treatment fdg uptake in certain regions of the normal lung correlated to the development of radiation induced lung toxicity after radiotherapy? an in-silico trial with a novel approach: the "virtual patient": fusing data from multiple lung cancer patients into a common spatial reference
Authors: Georgi Nalbantov, Wouter Van Elmpt, Andre L. A. J Dekker, Bianca Hanbeukers, Guillaume Janssens, Dirk De Ruysscher, Steven Petit, Philippe Lambin
Journal: Journal of Thoracic Oncology (2011)
The Decision for Liver Transplant in Acute on Chronic Liver Failure (ACLF) - First Week is the Crucial Period - Analysis of the Apasl ACLF Research Consortium (AARC) Prospective Data of 1021 Patients
Authors: A.K. Choudhury, M.K. Sharma, R. Maiwal, P. Jain, M.A. Mahtab, Y.K. Chawla, S.S. Tan, Q. Ning, H. Devarbhavi, D.N. Amarapurkar, C.W. Kim, S.S. Sadiq, A.S. Butt, C. Eapen, H. Ghazinyan, C. yu, A. Sood, G.H. Lee, Z. Abbas, G. Shiha, L.A. Lesmana, D.A. Payawal, K.A. Dokmeci, G.K. Lau, S.K. Sarin
Journal: Journal of Hepatology (2016)
Diagnostic Algorithm for High Liver Iron Overload: Results from a Prospective Study of 312 Patients with Hyperferritinemia
Authors: E. Zapata, A. Castiella, I. Urreta, J.M. Alústiza, E. Salvador, P. Otazua, M.D. De Juan, G. Letamendi, B. Arrizabalaga, L. Zubiaurre, U. Mendarte, M.L. Rincon, J.I. Emparanza
Journal: Journal of Hepatology (2016)
Cost-utility analysis of anastrozole vs tamoxifen in postmenopausal women with early breast cancer from a UK national health service perspective: The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial
Authors: R. E. Mansel
Journal: Journal of Clinical Oncology (2005)

653 Background: The completed treatment analysis of the ATAC trial (median follow-up of 68 months) confirmed the superior efficacy and tolerability of anastrozole over tamoxifen as primary adjuvant therapy for postmenopausal (PM) women with hormone receptor-positive (HR+) early breast cancer (EBC). The impact of such a change in treatment on UK National Health Service (NHS) budget holders was assessed by calculating the incremental cost per quality-adjusted life-year (QALY) gained for anastrozole vs generic tamoxifen. Methods: A probabilistic Markov model was developed to project outcomes for a hypothetical cohort of 1000 PM women with HR+ EBC over a 25-year time horizon (lifetime equivalent), based primarily on clinical data from the completed treatment analysis of the ATAC trial, resource utilization data from a physician survey and published literature. Unit costs (2003–4 UK£) were obtained from routine NHS sources. In the base-case analysis, the Kaplan-Meier recurrence curves were considered to show continued benefit for anastrozole to 10 years from initiation of treatment. Utility scores, derived from a study of 26 UK patients with EBC, were incorporated into the model to calculate a cost per QALY gained. Costs and benefits were discounted at the annual rate of 3.5%. Results: In 1000 PM women with HR+ EBC, the model showed that anastrozole would lead to a gain of 246 QALYs (or 232 life years) at an additional cost of £2.9 million compared with tamoxifen. The incremental cost-effectiveness of anastrozole versus tamoxifen at 25 years was £11,608 per QALY gained (or £12,291 per life-year gained). Cost-effectiveness acceptability curves showed a greater than 90% probability that the cost per QALY gained with anastrozole would be lower than £30,000. The results of the model were robust in a sensitivity analysis. Conclusions: Compared with commonly accepted thresholds, anastrozole is a cost-effective alternative to generic tamoxifen for the primary adjuvant treatment of PM women with HR+ EBC from the UK NHS perspective. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca AstraZeneca AstraZeneca AstraZeneca
A Second Autologous Stem Cell Transplant (ASCT2) Induces Superior Durability Of Response (DuR) Following Bortezomib-Containing Re-Induction Therapy For Relapsed Multiple Myeloma (MM): Final Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial
Authors: Gordon Cook, Cathy D. Williams, David A Cairns, Marie Fletcher, J. D. Cavenagh, John A Snowden, Christopher Parrish, John Ashcroft, Kwee L Yong, Jim Cavet, Hannah Hunter, Jennifer Bird, Sheila J O'Connor, Julia MB Brown, Treen Morris
Journal: Blood (2013)
Validation of the New European LeukemiaNet (ELN) Recommendations for Bcr-Abl Kinase Domain Mutation Analysis In Chronic Myeloid Leukemia: An Analysis of the GIMEMA CML Working Party Studies
Authors: Simona Soverini, Alessandra Gnani, Caterina De Benedittis, Fausto Castagnetti, Gabriele Gugliotta, Maria Teresa Bochicchio, Francesca Palandri, Mario Arpinati, Francesca Bonifazi, Elisabetta Abruzzese, Federica Sorà, Giuliana Alimena, Patrizia Pregno, Giorgina Specchia, Domenico Russo, Fabrizio Pane, Giuseppe Saglio, Marzia Salvucci, Alfonso Zaccaria, Giovanni Poletti, Barbara Giannini, Ilaria Iacobucci, Annalisa Lonetti, Sandra Durante, Gianantonio Rosti, Michele Baccarani, Giovanni Martinelli
Journal: Blood (2011)
Dissociation between Clinical Evaluation and Peld Score in the Setting of Pediatric Living-Related Liver Transplantation in Japan: A Eighteen Year Single Center Experience
Authors: K. Bessho, Y. Hasegawa, H. Fukuda, K. Hagiwara, T. Ueno, Y. Miyoshi, H. Kondou, S. Mushiake, H. Okuyama, K. Ozono
Journal: Journal of Hepatology (2016)
Abstract 4336: Direct genotyping of CYP2A6 whole gene deletion: A new biomarker for prognosis of lung adenocarcinoma in Japanese smoking male
Authors: Yasuko Okano, Yasushi Ichikawa, Yohei Miyagi, Takashi Chishima, Yutaka Natsumeda
Journal: Cancer Research (2015)

Abstract Purpose: Cytochrome P450 (CYP2A6) is known as an enzyme responsible for the metabolism of activation of tobacco-specific nitrosamines to their ultimate carcinogenic forms and metabolism of nicotine. We here report that the genetic polymorphisms of human CYP2A6*4 is associated with primary lung cancer and their overall survival. Experimental Design: We prepared genomic DNA samples from 387 Japanese patients with primary lung cancer and the genetic polymorphisms of human CYP2A6*4 (whole gene deletion) by the rapid genetic testing method we developed in this study. We analyzed the association between the CYP2A6*4 gene, NRF2 gene and overall survival. Results: Patients harboring wild-type CYP2A6*1 and whole gene deletion CYP2A6*4/*4 numbered 380 (98.2%) and 7 (1.8%), respectively. Its frequency was four-fold higher in male patients than in female (P = 0.038).Multivariate logistic regression models revealed that the genetic polymorphisms of human CYP2A6*4 were significantly related to gender and smoking behavior. Interestingly, lung cancer patients carrying CYP2A6*4/*4 (whole gene deletion), the NRF2 SNP heterozygous (c.-617C/A) and wild-type homozygous (c.-617C/C) exhibited remarkable survival over 1,500 days after surgical operation. Conclusion: CYP2A6*4/*4 whole gene is considered to be a prognostic biomarker for assessing both the gender-related risk of lung adenocarcinoma in the smoking sub-population and their overall survival. Citation Format: Yasuko Okano, Yasushi Ichikawa, Yohei Miyagi, Takashi Chishima, Yutaka Natsumeda. Direct genotyping of CYP2A6 whole gene deletion: A new biomarker for prognosis of lung adenocarcinoma in Japanese smoking male. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4336. doi:10.1158/1538-7445.AM2015-4336